A new ABC half-transporter in Leishmania major is involved in resistance to antimony by Manzano, José Ignacio et al.
A New ABC Half-Transporter in Leishmania major Is Involved in
Resistance to Antimony
J. I. Manzano, R. García-Hernández, S. Castanys, F. Gamarro
Instituto de Parasitología y Biomedicina “López-Neyra,” IPBLN-CSIC, Parque Tecnológico de Ciencias de la Salud, Armilla, Granada, Spain
The characterization of ABCI4, a new intracellular ATP-binding cassette (ABC) half-transporter in Leishmania major, is de-
scribed. We show that ABCI4 is involved in heavy metal export, thereby conferring resistance to Pentostam, to Sb(III), and to
As(III) and Cd(II). Parasites overexpressing ABCI4 showed a lower mitochondrial toxic effect of antimony by decreasing reactive
oxygen species production andmaintained higher values of both the mitochondrial electrochemical potential and total ATP lev-
els with respect to controls. The ABCI4 half-transporter forms homodimers as determined by a coimmunoprecipitation assay. A
combination of subcellular localization studies under a confocal microscope and a surface biotinylation assay using parasites
expressing green fluorescent protein- and FLAG-tagged ABCI4 suggests that the transporter presents a dual localization in both
mitochondria and the plasmamembrane. Parasites overexpressing ABCI4 present an increased replication in mouse peritoneal
macrophages. We have determined that porphyrins are substrates for ABCI4. Consequently, the overexpression of ABCI4 con-
fers resistance to some toxic porphyrins, such as zinc-protoporphyrin, due to the lower accumulation resulting from a signifi-
cant efflux, as determined using the fluorescent zinc-mesoporphyrin, a validated heme analog. In addition, ABCI4 has a signifi-
cant ability to efflux thiol after Sb(III) incubation, thus meaning that ABCI4 could be considered to be a potential thiol-X-pump
that is able to recognize metal-conjugated thiols. In summary, we have shown that this new ABC transporter is involved in drug
sensitivity to antimony and other compounds by efflux as conjugated thiol complexes.
Despite being prevalent in 98 countries spread across threecontinents, leishmaniasis, which is caused by the protozoan
parasite Leishmania, is one of the most neglected tropical diseases
(1). The estimated incidence of leishmaniasis is over 12 million
peopleworldwide, and it is responsible for a variety of pathologies,
ranging from self-healing cutaneous lesions to fatal visceral infec-
tion (1). Since there are currently no effective vaccines, treatment
largely relies on chemotherapy, although its efficacy is increasingly
limited by growing resistance to first-line drugs, especially anti-
monials, the frequent side effects associatedwith their use, and the
high cost of treatment (1). The recommended first-line therapies
for visceral leishmaniasis (VL) include: (i) pentavalent antimoni-
als (meglumine antimoniate and sodium stibogluconate), except
in some regions in the Indian subcontinent where there are signif-
icant areas of drug resistance (2); (ii) the polyene antibiotic am-
photericin B; (iii) the liposomal formulation AmBisome; (iv) the
aminoglycoside paromomycin; and (v) the oral drug miltefosine.
Although the World Health Organization (WHO) (1, 3) recently
recommended the use of either a single dose of AmBisome or
combinations of antileishmanial drugs in order to reduce the du-
ration and toxicity of treatment, prolong the therapeutic life span
of existing drugs and delay the emergence of resistance, recent
experimental findings have demonstrated the ability of Leishma-
nia to develop resistance to different drug combinations (4).
One of the main problems of leishmaniasis chemotherapy is
the growing antimonial resistance found in Indian VL. Studies
concerning experimental resistance to antimony in Leishmania
indicate that several mechanisms may occur concurrently in the
same parasite and that different mechanisms may operate in field
isolates compared to lab-generated resistant Leishmania lines (5,
6). One mechanism of resistance to antimony in Leishmania in-
volves a reduction in its accumulation, either by reduced uptake
or increased efflux, with the latter being mediated by the ABC
transporter ABCC3 (also known as PGPA or MRPA) (7, 8). ABC
transporters constitute one of the largest families of proteins de-
scribed and as such play a broad variety of physiological roles with
major medical consequences. These proteins are evolutionarily
highly conserved, they are present in species ranging from pro-
karyotes to humans (9), and they use the energy provided by ATP
hydrolysis to transport different compounds across biological
membranes, including a variety of leishmanicidal agents such as
antimonials (10), miltefosine (11), pentamidine (12), and sitama-
quine (13).
Functional ABC transporters consist of two homologous
halves, each of which is composed of a transmembrane domain
(TMD) involved in substrate binding and a cytosolic nucleotide
binding domain (NBD), which hydrolyzes ATP (9). Some ABC
transporters are half-transporters with an NBD-TMD or TMD-
NBD topology that requires homo-/hetero-dimerization to be-
come functional (14). The Leishmania genome contains 42 ABC
genes, with representative members from every subfamily (from
ABCA to ABCH) commonly found in eukaryotes (15). To date,
only ABC transporters related to the ABCA, ABCB, ABCC, and
ABCG subfamilies have been described in Leishmania (10, 16).
At least two transporters from the ABCC family appear to be
involved in antimony resistance (17). The Leishmania ABCC3,
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which is located in the intracellular vesicular membrane close to
the flagellar pocket, has been reported to be involved in arsenite
and antimonial resistance in the promastigotes and amastigotes of
several metal-resistant Leishmania species (18, 19). In addition,
this transporter presents the ability to transport thiol-conjugated
metals (19).
One of the proposed mechanisms of resistance to antimony
suggests that conjugation with a thiol and extrusion of the com-
plex by an ATP-coupled pump present in the plasma membrane
(PM) is required (20).However, this transport system is not found
for the ABCC proteins of Leishmania since all proteins of this
subfamily have an intracellular location (21). Since there is cur-
rently very little understanding of the transporter responsible for
this antimony efflux system (22), further studies are required to
understand themechanism of antimony resistance in Leishmania.
The involvement of thiols in antimony resistance is supported
by an increase in the levels of the enzymes responsible for thiol
synthesis (-glutamylcysteine synthetase and ornithine decarbox-
ylase) in experimental metal-resistant Leishmania lines and in
clinical isolates resistant to Pentostam (GlaxoSmithKline) (23,
24). Furthermore, this resistant phenotype can be reverted by bu-
thionine sulfoximine (BSO), a biosynthesis-specific glutathione
inhibitor (19). Similarly, the capacity of Leishmania ABCC3 to
efflux toxic metals is known to be accompanied by a decreased
generation of reactive oxygen species (ROS), thus contributing to
decreased antimonial toxicity (25).
The secondABC transporter involved in antimony resistance is
ABCC7-PRP1 (12, 17), a gene that is overexpressed in pentami-
dine-resistant Leishmania lines and confers significant cross-resis-
tance to antimony (26). However, no clear association has been
found between the amplification/overexpression of PRP1 and
pentamidine resistance (27). As described recently, no other
ABCC proteins have been demonstrated to be amplified or over-
expressed in antimony-resistant Leishmania lines (17).
Here, we report the characterization of a new ABC transporter
(ABCI4) in Leishmania major that is included in the unclassified
group of ABC proteins termed as “others” (15).We have renamed
this groupABCI, similar to what has been proposed for plant ABC
classification (53). This transporter encodes a half-transporter
with a TMD-NBD topology that requires at least homodimeriza-
tion, with a dual localization at the PM andmitochondria. ABCI4
has antimony and other heavy metals as potential substrates,
thereby conferring resistance to antimonials due to the lower ac-
cumulation resulting from their active efflux. As such, we postu-
late that ABCI4 could be considered to be a potential thiol-X-
pump that is able to recognize metal-conjugated thiols, thereby
conferring antimony resistance in Leishmania.
MATERIALS AND METHODS
Chemical compounds. Carbonylcyanide p-trifluoromethoxyphenylhy-
drazone (FCCP), trivalent antimony (Sb(III); potassium antimony
tartrate), pentamidine, paromomycin, amphotericin B, ketoconazole,
chloroquine, quinine, mefloquine, primaquine, 4=,6-diamidino-2-phe-
nylindole dilactate (DAPI), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT), BSO, CdCl2, CoCl2, CuSO4, Pb(NO3)2,
NaAsO2, MnCl2, ZnCl2, n-dodecyl--D-maltopyranoside (DDM), pheo-
phorbide A, and glutathione (GSH) were purchased from Sigma-Aldrich
(St. Louis,MO).Miltefosinewas purchased fromÆterna Zentaris (Frank-
furt, Germany) and daunomycin (DNM) was purchased from Pfizer
(Madrid, Spain). All chemicals were of the highest quality available.
Pentostam, tafenoquine, and sitamaquine dihydrochloridewere provided
by GlaxoSmithKline (Greenford, United Kingdom). MitoSOX Red,
H2DCFDA, and JC-1 were purchased from Invitrogen (Carlsbad, CA).
Zinc-protoporphyrin and zinc-mesoporphyrin were purchased from
Frontier Scientific (Logan, UT).
Animals. Six-week-old male BALB/c mice were purchased from
Charles River Breeding Laboratories and maintained in the Animal Facil-
ity Service of our Institute under pathogen-free conditions. They were fed
a regular rodent diet and given drinkingwater ad libitum. Thesemicewere
used to collect primary peritoneal macrophages.
Ethics statement. All experiments were performed according to
National/EU guidelines regarding the care and use of laboratory ani-
mals in research. Approval for these studies was obtained from the
Ethics Committee of the Spanish National Research Council (CSIC file
CEA-213-1-11).
Leishmania culture conditions. The promastigotes of L. major
(MHOM/JL/80/Friedlin) and derivative lines used in the present study
were cultured at 28°C inM-199medium (Invitrogen) supplemented with
10% heat-inactivated fetal bovine serum (hiFBS; Invitrogen).
In vitro infection of mouse peritoneal macrophages. Amastigotes
were cultured for 24 and 72 h in infected peritoneal macrophages from
BALB/c mice (Charles River, Ltd.) as described previously (28).
DNAconstructs and site-directedmutagenesis.ABCI4 fromL.major
(GeneDB L. major, accession code LmjF.33.3260) was isolated from the
genomic DNA of L. major by PCR using sense (5=-TGCATTCTCACGCC
TTCACAC) and antisense (5=-ACTAGCATTAGCTGCGAGTTCC)
primers. ABCI4 was cloned into the Leishmania expression vector pXG-
Hyg (29) and sequenced. The Leishmania expression vectors pXG-=GFP
and pXG-GFP2= (29) were used to construct chimeric ABCI4 fusion
proteins with a green fluorescent protein (GFP) at the C- and N-terminal
positions, respectively. For the C-terminal position of GFP, ABCI4 was
amplified by PCR using sense (5=-ATAGATCTATGAGACTCACTGATG
CTCCGT) and antisense (5=-ATGATATCGCTCACTGCCTGTGCACG)
primers. For the N-terminal position of GFP, ABCI4 was amplified using
sense (5=-ATGCGGCCGCATGAGACTCACTGATGCTCCGT) and anti-
sense (5=-ATAGATCTTCAGCTTCACTGCCTGTGC) primers. To ob-
tain parasites expressing nonfunctional ABCI4, a mutation was intro-
duced in the Walker A motif, replacing lysine 742 for methionine
(K742M) using the QuikChange XL site-directed mutagenesis kit (Strat-
agene, La Jolla, CA) and the sense (5=-GTGGGGCGGGGATGAGTACG
CTGCT) and antisense (5=-AGCAGCGTACTCATCCCCGCCCCAC)
primers. To incorporate an N-terminal FLAG epitope tag, ABCI4 was
amplified by using sense (5=- ATGGACTACAAGGACGACGACGACAA
GATGAGACTCACTGATGCTCC) and antisense (5=-TCAGCTCACTG
CCTGTGCAC) primers. Similarly, sense (5=-ATGGACTACAAGGACGA
CGACGACAAGGACTACAAGGACGACGACGACAAGGACTAC) and
antisense (5=-TCAGCTCACTGCCTGTGCAC) primers were used to add
two additional FLAG epitope tags to the previous construct. These con-
structs were cloned into the expression vector pXG-Hyg.
Gene expression. Total RNAwas extracted from different Leishmania
lines using the high pure RNA isolation kit (Roche Diagnostics GmbH,
Germany) and transcribed into cDNA using the qScript cDNA synthesis
kit (Quanta Biosciences, Inc.) according to the manufacturer’s instruc-
tions. The cDNA obtained was diluted (1:10 and 1:50) and amplified with
sense (5=-TGACGAGCATGAAGCGTACAC) and antisense (5=-GCTGT
ATCGATGCAGGCCT) primers for ABCI4 and with sense (5=-GAAGTA
CACGGTGGAGGCTG) and antisense (5=-CGCTGATCACGACCTTC
TTC) primers for GADPH (as internal control) and electrophoresed on
1% agarose gel.
Cell transfection and sensitivity analysis. Parasites transfected with
the constructs obtained above were selected for hygromycin or G418 de-
pending on the vector used in each construct, as described previously (30).
In addition, the Leishmania line overexpressing ABCI4K/M was cotrans-
fected with ABCI4 to rescue the phenotype induced by the mutant line.
The sensitivity of L. major promastigote lines to different compounds was
determined using the MTT colorimetric assay, as described previously
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(31). The 50% effective concentration (EC50) is the concentration of drug
that decreases the rate of cell growth by 50%. To determine the relation-
ship between thiol levels and the sensitivity of the different Leishmania
lines, 3mMBSO (a -glutamylcysteine synthetase inhibitor) was added at
28°C for 48 h before the sensitivity experiments. The sensitivity of intra-
cellular Leishmania amastigotes to Sb(III) and Sb(V) (Pentostam) was
determined after 72 h of incubation as described previously (28).
Fluorescence microscopy of Leishmania promastigotes. Promasti-
gotes expressing ABCI4 GFP-fused proteins were used for localization
studies. Parasite mitochondria were labeled with 50 nMMitoTracker Red
(Invitrogen) for 30 min at 28°C in RPMI medium without hiFBS. They
were then washed with phosphate-buffered saline (PBS) and analyzed
under an Axiovert confocal microscope (TCS SP5 model; Leica).
Cell surface biotinylation. Parasite surfaces were labeled as described
previously (32), using 3% DDM instead of 1% Nonidet P-40 for parasite
lysis. Protein samples were fractionated by SDS-PAGE under standard
conditions and then electrotransferred onto Immobilon P membranes
(Millipore, Bedford, MA). Immunodetection was performed using
1:5,000 polyclonal anti-GFP or 1:3,000 polyclonal anti-LRos3 (LRos3 is a
PM protein) (32), respectively, in PBS plus 0.01% Tween 20 and 0.1%
bovine serum albumin (BSA). Control of PM integrity was determined by
immunodetection with monoclonal anti--tubulin antibody (Sigma-Al-
drich) at 1:5,000. After washing, membranes were incubated with horse-
radish peroxidase-conjugated secondary goat anti-rabbit (1:5,000) im-
munoglobulin G (Dako, Barcelona, Spain) for GFP and LRos3, and rabbit
anti-mouse (1:5,000) immunoglobulin G (Dako) for -tubulin. Signals
were detected using the enhanced chemiluminescence (ECL) substrate
(Pierce).
Coimmunoprecipitation assays. Leishmania promastigotes (8 109)
expressing 3FLAG-ABCI4 and both 3FLAG- and GFP-ABCI4 chimeric
proteins were washed with PBS, resuspended in 1 ml of lysis buffer, and
disrupted for 45 min in a prechilled, high-pressure cavitator (Ashcroft,
USA) connected to a compressed nitrogen cylinder at 100 bar pressure.
The parasite lysates were centrifuged at 1,000 g to eliminate cell debris;
the supernatant was then centrifuged at 100,000  g and 4°C for 1 h to
obtain parasite membrane-enriched fractions. The pellets obtained were
solubilized in 550 l of lysis buffer supplemented with 2.5% DDM, and
the resulting solution clarified by centrifugation at 100,000 g at 4°C for
30 min. Supernatants were incubated with magnetic beads covalently
bound to anti-GFP for 24 h at 4°C. After incubation, the magnetic beads
were washed three times with lysis buffer supplementedwith 0.05%DDM
and elutedwith Laemmli buffer. Samples were fractionated by SDS-PAGE
under standard conditions and then electrotransferred onto Immobilon P
membranes (Millipore, Bedford, MA). Immunodetection was performed
using 1:5,000 polyclonal anti-GFP or 1:2,000 polyclonal anti-FLAG
(Pierce), respectively, in wash solution (PBS plus 0.01% Tween 20 and
0.1% BSA). Membranes were incubated with horseradish peroxidase-
conjugated secondary goat anti-rabbit (1:5,000) immunoglobulin G
(Dako), and signals were detected using the ECL substrate (Pierce).
Antimony accumulation and efflux by ICP-MS. Promastigotes (108
perml)were incubatedwith 100MSb(III) inM-199 culturemedium for
different time points at 28°C and then centrifuged, and the resultant pellet
stored at 80°C until measurement of antimony accumulation as de-
scribed previously (7). To determine antimony efflux, the different lines
were incubated with compensated Sb(III) concentrations (100 M for
pXG and ABCI4K/M lines and 200M for ABCI4 line) in culture medium
at 28°C for 1 h to allow a similar labeling in the Leishmania lines. The
parasites were then washed with PBS, resuspended in culture medium at
28°C, and pelleted at different time points. The cell pellet was dissolved in
200 l of concentrated nitric acid for 24 h at room temperature. The
sample was diluted to 3 ml with distilled water and then injected into an
inductively coupled plasma mass spectrometer (ICP-MS; Perkin-Elmer)
for quantitation.
Cadmium accumulation and efflux. Cadmium (Cd(II)) accumula-
tion assays were performed using the fluorimetric dye Leadmium Green
(Invitrogen), as described previously for mammalian cells (33). Thus,
promastigotes (107) were incubated with 100 M Cd(II) in saline buffer
(21 mM HEPES, 137 mM NaCl, 5 mM KCl, 6 mM glucose; pH 7) for
different time points at 28°C. The parasites were then pelleted andwashed
twice with saline buffer. Sample fluorescence was measured using an In-
finite F200 luminescence system (Tecan Austria GmbH). To determine
Cd(II) efflux, pXG and ABCI4 lines were incubated with compensated
concentrations of the metal (100 and 175 M, respectively), according to
the results obtained in the accumulation experiments. After incubation
for 1 h, parasites were centrifuged, washed twice with saline buffer, and
then resuspended in the same buffer. The fluorescence retained was mea-
sured at different time points as described above.
Zinc-mesoporphyrin accumulation and efflux. Promastigotes in
their logarithmic phase were washed and resuspended in HPMI medium
(120mMNaCl, 5mMKCl, 400MMgCl2, 40MCaCl2, 10mMHEPES,
10 mMNaHCO3, 10 mM glucose, 5 mMNa2HPO4) at a final concentra-
tion of 5 107 promastigotes/ml. The parasites were then incubated with
10Mzinc-mesoporphyrin (ZnMP) at 28°C for 10 min and washed with
PBS buffer plus 5% BSA. Finally, the parasites were fixed with 2% para-
formaldehyde in PBS, and the fluorescence retainedwasmeasured by flow
cytometry (excitation at 405 nm and emission at between 575 and 585
nm) using a FacsAria Cell Sorter III (Becton Dickinson, San Jose, CA). To
determine the ZnMP efflux, the Leishmania control line (pXG) and
ABCI4K/M were loaded with 10 M ZnMP, whereas the Leishmania line
overexpressing ABCI4 was loaded with 20 M in order to allow for a
similar labeling in HPMI medium at 28°C. The parasites were subse-
quently washed with PBS, and efflux was measured by determination of
the fluorescence retained at different time points by flow cytometry as
described above.
Pheophorbide A accumulation and efflux. Determination of the ac-
cumulation and efflux of pheophorbide A, a phototoxic porphyrin catab-
olite of chlorophyll, was performed as described previously (34), with
some modifications. Briefly, parasites (107) were resuspended in 1 ml of
HPMImedium and incubated with 10Mpheophorbide A for 30 min at
28°C. The parasites were them washed with PBS buffer and the fluores-
cence retainedmeasured by flow cytometry using a FACScan flow cytom-
eter (Becton Dickinson). For pheophorbide A efflux, after incubation
with 10 M pheophorbide A, the parasites were washed with PBS and
resuspended in HPMI medium for 60 min at 28°C. The fluorescence re-
tained was measured as described above.
Determination of nonprotein thiol. Intracellular nonprotein thiol
levels were measured by flow cytometry using CellTracker, as described
previously (35). Thiol effluxed to the culture medium was determined
using the thiol fluorescent detection reagent ThioStar (Luminos, Ann
Arbor, MI) (36). Thus, parasites (108) were incubated with 100 M
Sb(III) for 1 h in 1 ml of HBS buffer (21 mMHEPES, 0.7 mMNa2HPO4,
137 mM NaCl, 5 mM KCl, and 6 mM glucose, pH 7), washed twice with
PBS buffer and then resuspended again in Sb(III)-free HBS buffer. Para-
sites were collected at different time points, and both the supernatants and
the pellets obtained were treated with 12% trichloroacetic acid at 4°C for
30 min to deproteinize and then centrifuged at 13,000 g. The superna-
tants were diluted with HBS buffer to reduce the trichloroacetic acid con-
centration to 2% and were then transferred to a 96-well microplate and
incubated with 3 g of ThioStar/ml for 1 h at room temperature. Sample
fluorescence (excitation, 380 nm; emission, 510 nm) was measured using
an Infinite F200 luminescence system (Tecan Austria GmbH). Different
GSH concentrations were used as a control of the thiol concentration
dependence signal of ThioStar.
Measurement of ATP and mitochondrial membrane potential
(m). ATP was measured using a CellTiter-Glo luminescence assay,
which generates a luminescent signal proportional to the amount of ATP
present, as described previously (28).	m was measured by flow cytom-
etry using the JC-1 fluorescent marker. Depolarization of 	m is indi-
cated by a reduced accumulation of the dye and a shift from red to green,
with a corresponding decrease in the red/green fluorescence ratio. The
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parasites (4 106 promastigotes/ml) were incubatedwith 100MSb(III)
for different time points at 28°C in HBS buffer and then washed twice,
resuspended in PBS, and further incubated at 28°C with 5M JC-1 for 10
min inHBS buffer. Cellular fluorescence was quantified by calculating the
ratio between FL2 andFL1using a FACScanflow cytometer (BectonDick-
inson). Parasites fully depolarized by incubation in 10 M FCCP for 10
min at 28°C were used as controls.
Measurement of ROS production. The generation of intracellular
ROS was measured in parasites exposed to increasing concentrations of
Sb(III) for 48 h using the cell-permeant H2DCFDA and MitoSOX Red
probes, as described previously (37). The fluorescence retained was mea-
sured by flow cytometry using a FACScan flow cytometer (Becton Dick-
inson).
Statistical analysis. Statistical comparisons between groups were per-
formed using Student t test. Differences were considered significant at a
level of P
 0.05.
RESULTS
Sequence features ofABCI4 and generationof aLeishmania line
expressing an inactive version of the protein. The present study
focuses on characterization of the ABCI4 gene (GeneDB L. major,
accession code LmjF.33.3260) fromchromosome 33, and grouped
as “others” according to the recently proposed classification (15).
ABCI4 codes for a 949-amino-acid protein, with a predicted mo-
lecular mass of103 kDa. ABCI4 shares a significant percentage
amino acid identity just in the NBD with other Leishmania ABC
transporters of ca. 30% for the ABCB subfamily. In addition, a
similar percent amino acid identity in the NBD domain was ob-
served with other eukaryotic ABC transporters, as for human
ABCB6 and ABCB7 transporters.
Hydrophobicity plots of ABCI4 using the programs TMpred
(http://www.ch.embnet.org/software/TMPRED_form.html) and
MEMSAT-SVM (http://bioinf.cs.ucl.ac.uk/psipred/ [data not
shown]) showed the expected topology for an ABC half-trans-
porter, with a hydrophilic region, which bears the highly con-
servedmotifs of ABC transporters (NBD) at the COOH terminus,
and a hydrophobic region (TMD), containing six putative trans-
membrane segments at the NH2 terminus.
The dimerization requirement for ABC half-transporters to
become functional led us to test a dominant-negative approach
to downregulate ABCI4 function, as recently described for
Leishmania LABCG5 and LABCG2 (38). To this end, we first
mutated the lysine residue inside the Walker A motif in ABCI4
(742 position), which is known to be critical for ATP hydrolysis
in ABC transporters (38, 39), to a methionine (K742M). The
expression of other ABCG half-transporters with a similar K/M
substitution produces a dominant-negative inhibition in the
wild-type transporters (38, 40). The resulting construct was
transfected into L. major and the expression of ABCI4K742M
(ABCI4K/M), as well as other Leishmania lines overexpressing
ABCI4 was verified by reverse transcription-PCR (RT-PCR)
(see Fig. S1 in the supplemental material). In contrast to the
phenotype observed after LABCG5K/M expression (38), para-
sites transfected with ABCI4K/M grew at normal rates (data not
shown).
Localization ofABCI4 inmitochondria andPMusing confo-
cal microscopy and biotinylation assay. To ascertain the subcel-
lular localization of ABCI4, we fused ABCI4 and ABCI4K/M with
an N-terminal GFP tag. These constructs were transfected into L.
major promastigotes and overexpression of the corresponding
proteins determined by Western blot analysis of whole parasite
lysates. As expected, a band corresponding to GFP-ABCI4 was
observed at130 kDa (see Fig. S2 in the supplemental material).
Fluorescencemicroscopy studies showed that GFP-ABCI4mainly
colocalizes with themitochondrial markerMitoTracker (Fig. 1A).
In addition, the protein that localizes at the PMof the parasite was
observed, although with a lower fluorescence intensity (Fig. 1A).
The localization pattern of the protein did not change when GFP-
ABCI4K/M was expressed in Leishmania parasites (data not
shown). Despite several attempts, we were unable to obtain para-
sites expressing GFP-tagged ABCI4 at the COOH terminus, thus
FIG 1 ABCI4 localizes to the mitochondria and PM of Leishmania parasites.
(A) Confocal microscopy images of L. major stationary promastigotes trans-
fected with GFP-ABCI4. (a) Nomarski image. (b) Green fluorescence associ-
ated with the GFP-ABCI4 fusion protein. (c) Red fluorescence associated with
parasites incubated at 28°C with 50 nMMitoTracker Red for 30 min. (d) The
merged image indicates colocalization (yellow) of ABCI4 with the mitochon-
drial probe. The figure illustrates a representative parasite from a total popu-
lation of parasites with a similar fluorescence pattern. The arrow indicates the
localization of ABCI4 in the PM. (B) ABCI4 expression levels in the PMmem-
brane by surface biotinylation. Biotinylated proteins from the promastigote
surface were analyzed by immunoblotting with anti-GFP, anti-LRos3, and
anti--tubulin antibodies as described in Materials and Methods. Western
blot assays representative of at least three independent experiments are shown.
(C) Coimmunoprecipitation experiments demonstrate that ABCI4 forms ho-
modimers. The solubilized membrane-enriched fraction of Leishmania para-
sites (a and b) overexpressing 3FLAG-ABCI4 (lane 1) and 3FLAG-ABCI4
andGFP-ABCI4 (lane 2) was incubatedwithmagnetic beads covalently bound
to anti-GFP. After incubation, the magnetic beads were washed, eluted and
analyzed by immunoblotting (c andd). The positions ofmolecularmassmark-
ers (in kilodaltons) are indicated on the left.
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suggesting that the C-terminal region is critical for maintaining
ABCI4 stability. We also determined that ABCI4 is localized to
mitochondria and PM using a FLAG-tagged ABCI4 (data not
shown). Overall, these studies suggest that ABCI4 has a dual lo-
calization in both mitochondria and the PM of Leishmania.
Surface biotinylation experiments showed thatGFP-ABCI4 lo-
calizes at the PM (Fig. 1B). ABCI4 was detected in the fraction
eluted from streptavidin beads by immunoblotting with anti-GFP
(Fig. 1B). LRos3, which is known to be present at the PM of Leish-
mania parasites (41), was used as a positive control (Fig. 1B).
Furthermore, no immunoreactive bands were detected after im-
munoblotting of biotinylated proteins against anti--tubulin
(Fig. 1B). This control confirms that the labeling reagent did not
penetrate the PM, thereby demonstrating the specificity of the
biotinylation procedure.
The dimerization requirement for ABC half-transporters to
become functional led us to determine whether ABCI4 forms ho-
modimers or heterodimers to be functionally active. The coim-
munoprecipitation assay was performed using parasites coex-
pressing GFP- and 3FLAG-ABCI4, and the proteins bound to
magnetic bead anti-GFP fractions were visualized by immuno-
blotting with anti-GFP and anti-FLAG antibodies. Western blot
analysis showed that anti-FLAG and anti-GFP antibodies detected
a specific band of the expected size for tagged-ABCI4 in parasites
overexpressing 3FLAG-ABCI4 and coexpressing 3FLAG-
ABCI4 and GFP-ABCI4 (Fig. 1Ca and b). The coimmunoprecipi-
tation assays revealed that anti-FLAG antibody only detected a
specific band only in the eluted fraction of parasites coexpressing
3FLAG-ABCI4 and GFP-ABCI4 after incubation of the solubi-
lized membrane-enriched fraction with magnetic beads cova-
lently bound to anti-GFP (Fig. 1Cc), thus suggesting that ABCI4
forms homodimers.
Overexpression of ABCI4 confers resistance to metal ions,
antimonials, and toxic porphyrins in Leishmania. Since several
ABC transporters have been implicated in drug resistance inLeish-
mania (10–13), we analyzed whether overexpression of ABCI4
could confer resistance against several compounds. Different un-
related antileishmanial drugs and other unrelated compounds
with potential use as antiprotozoal drugs, including Sb(III), am-
photericin B, miltefosine, paromomycin, aminoquinolines (sita-
maquine, tafenoquine, chloroquine, mefloquine, and prima-
quine), quinine, azoles (ketoconazole), daunomycin, and As(III),
were tested (Table 1). Parasites overexpressing ABCI4 were 2-
fold more resistant to Sb(III) and As(III) than the control (para-
sites transfectedwith the empty vector pXG). These results suggest
that metal ions are possible substrates for ABCI4 (Table 1). Fur-
ther analysis showed that overexpression of ABCI4 conferred re-
sistance to the metal ions Cd(II) and Pb(II) but did not affect the
susceptibility to Cu(II), Zn(II), Co(II), and Mn(II) (Table 2).
These results suggest that some heavy metals, mainly Sb(III), are
putative ABCI4 substrates. The above results were validated in a
second transfection event with ABCI4 (Table 2). Promastigotes
overexpressing GFP-ABCI4 showed similar behavior to parasites
overexpressing untagged ABCI4, thus showing that tagging at the
NH2 terminus did not interfere with the functionality of ABCI4
(Table 2). In addition, the cross-resistance profile obtained in
Leishmania promastigotes overexpressing ABCI4K/M was similar
to that for control parasites (Tables 1 and 2). To verify that the
TABLE 1 Drug resistance profile in L. major linesa
Drug
Mean EC50 (M) SD [RI]
b
pXG ABCI4 ABCI4K/M
Promastigote
Sb(III) 20.87 1.80 53.74 3.35 [2.6]* 21.16 3.60 [1.0]
As(III) 2.62 0.69 5.14 0.50 [2.0]* 1.97 0.36 [0.8]
Amphotericin B 0.14 0.01 0.11 0.01 [0.8] 0.09 0.01 [0.6]
Miltefosine 20.08 1.30 16.39 1.12 [0.8] 20.79 0.60 [1.0]
Paromomycin 25.36 2.36 27.54 3.21 [1.1] 26.31 0.97 [1.0]
Tafenoquine 4.98 0.20 4.90 0.16 [1.0] 3.47 0.28 [0.7]
Sitamaquine 11.52 1.23 11.72 1.52 [1.1] 11.09 0.98 [1.0]
Primaquine 3.69 0.37 4.14 0.65 [1.1] 2.27 0.24 [0.6]
Chloroquine 2.82 0.23 2.32 0.14 [0.8] 1.88 0.21 [0.7]
Ketoconazole 47.30 3.56 45.07 4.89 [1.0] 39.72 2.23 [0.8]
Daunomycin 9.09 0.36 9.54 0.23 [1.1] 9.71 0.36 [1.1]
Mefloquine 0.65 0.03 0.66 0.05 [1.0] 0.62 0.08 [1.0]
Quinine 25.11 1.45 33.23 3.60 [1.3] 22.46 2.14 [0.9]
ZPPc 4.35 0.67 10.12 0.23 [2.1]* 4.85 0.16 [1.1]
Pheophorbide Ac 10.01 0.15 8.61 0.53 [0.9] 8.90 0.66 [0.9]
Amastigote
Sb(III) 5.73 0.41 14.97 1.23 [2.6]* 6.45 0.12 [1.1]
Pentostam [Sb(V)] 28.06 1.98 53.09 2.34 [1.9]* 28.16 2.30 [1.0]
a Promastigotes were grown as described in Materials and Methods for 72 h at 28°C in the presence of increasing concentrations of drugs. Cell viability was determined by using an
MTT-based assay. On the other hand, intracellular amastigotes L. major lines were obtained after infection of mouse peritoneal macrophages with the different promastigote lines
using a macrophage/parasite ratio of 1:10. After 72 h, drug activity was determined from the percentage of infected cells and the number of amastigotes by cells in drug-treated
cultures versus nontreated cultures. The infection was determined by DAPI staining in 200 macrophages/well. Significant differences were determined by using the Student t test (*,
P
 0.01).
b Resistance indexes (RI) were calculated by dividing the EC50 for Leishmania line overexpressing ABCI4 or ABCI4
K/M by that for Leishmania line control (pXG). Data are means
from three independent experiments.
c Cell densities were measured with an electronic particle counter (Coulter Electronics, United Kingdom) and by direct counting with a hemocytometer.
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resistance to someheavymetals observed in parasites overexpress-
ing ABCI4 was due to overexpression of the ABC transporter,
ABCI4 parasites were cured for the plasmid pXG-Hyg (reverted
line, ABCI4rev) by culturing the parasites in the absence of plas-
mid drug selection pressure for 1 month. This reverted line
showed a similar resistance to some heavy metals as the control
(pXG) Leishmania line (Table 2). In addition, parasites coexpress-
ing ABCI4-ABCI4K/M showed similar Sb(III) sensitivity to the
controls (see Fig. S3 in the supplemental material). This finding
indicates that the mutated version of the transporter binds and
inhibits ABCI4 activity and also suggests a low basal expression
level of this transporter in wild-type parasites.
The Sb(III) resistance shown by the promastigote forms of
Leishmania was maintained in intracellular amastigotes obtained
after infection of mouse peritoneal macrophages (Table 1). Fur-
thermore, amastigotes overexpressing ABCI4 were also resistant
to Pentostam, a leishmanicidal drug containing pentavalent anti-
mony, which is reduced to Sb(III) in the amastigote forms. These
findings indicated that the resistance indices to antimonials in the
intracellular amastigotes overexpressing ABCI4 were very similar
to those observed in their promastigote counterparts (Tables 1
and 2).
As far as the mitochondrial localization of ABCI4 and the pos-
sibility of its involvement in heme transport is concerned, as de-
scribed for other ABC transporters, we determined whether por-
phyrins are a substrate for ABCI4, and consequently, whether the
overexpression of ABCI4 confers resistance to some toxic porphy-
rins such as zinc-protoporphyrin (ZPP), a validated heme analog,
and pheophorbide A, which is structurally related to protopor-
phyrins. As can be seen from Table 1, ABCI4 overexpression
ABCI4 confers a significant resistance to ZPP (2-fold) but not to
pheophorbide A. The mutant ABCI4K/M showed the same sensi-
tivity levels as observed in control parasites.
Reduction in the accumulation of Sb(III), Cd(II) and por-
phyrins due to an increased efflux in L. major overexpressing
ABCI4. To corroborate that ABCI4 has Sb(III) and Cd(II) as po-
tential substrates, the intracellular accumulation of these metal
ions was measured in L. major lines as a function of time by
ICP-MS and using the fluorimetric dye LeadmiumGreen, respec-
tively. Accumulation of Sb(III) and Cd(II) was found to be time-
dependent (Fig. 2A), with parasites overexpressing ABCI4 accu-
mulating 52% of the Sb(III) and 63% of the Cd(II) of control
parasites at the final incubation time (Fig. 2A). The lower Sb(III)
accumulation could explain the resistance to antimonials ob-
served in parasites overexpressing the ABCI4 transporter. To de-
termine whether the reduced level of accumulation of heavy met-
als in the resistant parasiteswas due to an increased efflux,L.major
lines were loaded under conditions that yielded similar amounts
of intracellular compounds and the amount of heavy metals re-
tained in the parasites measured at different time points. The ef-
flux of Sb(III) and Cd(II) was found to be time-dependent in the
Leishmania lines (Fig. 2A) and was faster for parasites overex-
pressing ABCI4, thus confirming that the differences in Sb(III)
andCd(II) accumulation are due to an increasedABCI4-mediated
efflux activity.
We also determined accumulation of the fluorescent zinc-
mesoporphyrin (ZnMP), as a validated heme analog, and found
that Leishmania parasites overexpressing ABCI4 present a lower
accumulation of ZnMP (2.1-fold) than controls (Fig. 2B) due to a
significant efflux (Fig. 2B). Parasites overexpressing ABCI4K/M
present a similar accumulation and efflux to control parasites (Fig.
2B). In contrast, the accumulation/efflux of pheophorbide A did
not differ between the Leishmania lines (data not shown), thus
supporting the sensitivity studies and suggesting that pheophor-
bide A does not interact with ABCI4.
Involvement of thiol in ABCI4-mediated drug resistance.An
increase in thiol levels has been considered to be one of the main
detoxification mechanisms observed in Leishmania lines selected
for resistance to Sb(III) (23). In light of this, we determined the
drug sensitivity profile for L. major lines overexpressing ABCI4 in
the presence of BSO (a -glutamylcysteine synthetase inhibitor).
After incubation with BSO (3 mM) for 48 h, Leishmania parasites
presented a decrease in thiol levels, asmeasured by flow cytometry
using CellTracker (data not shown). The drug sensitivity profile
for Leishmania lines treated with BSO showed a significant de-
crease in the EC50s for Sb(III) and Cd(II), with higher rates in
parasites overexpressing ABCI4 than ABCI4K/M or control (Table
3). Consequently, the Sb(III) and Cd(II) resistance of L. major
overexpressing ABCI4 is associated with the thiol levels in the
TABLE 2 Heavy metal sensitivity in L. major promastigote linesa
Metal
Mean EC50 (M) SD [RI]
b
pXG ABCI4c 2-ABCI4d ABCI4rev GFP-ABCI4e 3FLAG-ABCI4f ABCI4K/M
Sb(III) 20.87 1.80 53.74 3.35 [2.6]* 40.61 3.46 [2.0]* 21.92 0.36 [1.0] 63.46 2.12 [3.0]* 50.75 1.32 [2.5]* 21.16 3.60 [1.0]
As(III) 2.62 0.69 5.14 0.50 [2.0]* 4.97 0.19 [1.9]* 2.86 0.27 [1.0] 5.76 0.47 [2.2]* 5.06 0.37 [2.0]* 1.97 0.36 [0.8]
Cd(II) 42.36 4.12 82.55 8.84 [2.0]* 40.96 2.30 [1.0]
Pb(II) 825.54 25.36 1,321.22 52.14 [1.6]* 826.15 38.50 [1.0]
Cu(II) 164.31 5.45 221.73 4.73 [1.4] 162.63 4.50 [1.0]
Zn(II) 590.04 0.50 728.95 1.43 [1.2] 555.43 12.60 [0.9]
Co(II) 35.33 1.23 35.89 1.57 [1.0] 38.20 2.01 [1.1]
Mn(II) 30.27 2.96 32.68 1.25 [1.1] 32.13 2.63 [1.1]
a Parasites were grown as described in Materials and Methods for 72 h at 28°C in the presence of increasing concentrations of drugs. Cell viability was determined using an MTT-
based assay. Significant differences were determined by using the Student t test (*, P
 0.01).
b Resistance indexes (RI) were calculated by dividing the EC50 for Leishmania lines overexpressing ABCI4, GFP-ABCI4, 3FLAG-ABCI4, ABCI4
K/M, or reverted line (ABCI4rev) by
that for Leishmania control line (pXG). Data are means from three independent experiments.
c First ABCI4 transfection event in L. major.
d Second ABCI4 transfection event in L. major.
e L. major overexpressing ABCI4 fused to GFP in the N-terminal position.
f L. major overexpressing ABCI4 fused to 3FLAG epitope tag in the N-terminal position.
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parasites, probably due to the ability of the transporter to efflux
thiol-conjugated complexes.
Since both conjugation and extrusion of thiol adducts of
Sb(III) are required for resistance to antimonials (23), we ana-
lyzed the non-protein thiol efflux in L. major lines using ThioStar.
In the presence of Sb(III), L. major lines overexpressing ABCI4
showed significantly higher thiol efflux levels than control and
mutant lines (Fig. 3A). As expected, no differences in thiol efflux
levels were observed in the absence of Sb(III) (Fig. 3B). However,
we found that in parasites overexpressing ABCI4, the efflux of
ZnMP in Leishmania lines is not thiol-dependent (data not
shown). As a result, we suggest that ABCI4 confers resistance to
Sb(III) via an efflux of Sb(III)-thiol complex and that this trans-
porter could be considered to be a potential thiol-X-pump.
FIG 2 Time-dependent accumulation and efflux of Sb(III), Cd(II), and ZnMP in Leishmania lines. (A) L. major pXG (control; }), overexpressing ABCI4 ()
and ABCI4K/M (Œ) were incubated with 100 M Sb(III) (upper left graphic) or Cd(II) (upper right graphic), and samples were taken at different time points as
described in Materials andMethods. Antimony accumulation was measured by ICP-MS. For Cd(II) accumulation, samples were taken at different time points,
mixedwith LeadmiumGreen, and the fluorescence determined (upper right graphic) as described inMaterials andMethods. The efflux assaywas performed after
incubation of Leishmania lines with compensated concentrations of Sb(III) (lower left graphic) or Cd(II) (lower right graphic) for 1 h to ensure similar labeling
in the different lines. The parasites were then washed and resuspended in PBS buffer without Sb(III) or Cd(II) and pelleted at different time points. (B)
Promastigotes of L. major lines pXG (control; black histogram), ABCI4 (gray histogram), and ABCI4K/M (white histogram) were incubated with 10 MZnMP
for 10 min at 28°C, as described in Materials and Methods (left graphic). Relative fluorescence units (RFU). The efflux assay was performed in L. major lines
loaded with different compensated ZnMP concentrations in order to ensure similar labeling, as described in Materials and Methods (right graphic). In both
graphics, the accumulated fluorescence at different time points was measured by flow cytometry using a FacsAria Cell Sorter III. The data are the means the
SD of three independent experiments. Significant differences versus the control line were determined by using the Student t test (*, P
 0.01).
Antimony Transport by ABCI4 in Leishmania
August 2013 Volume 57 Number 8 aac.asm.org 3725
ATP and m levels in Leishmania lines overexpressing
ABCI4. It has previously been reported that antimony induces
mitochondrial dysfunction in Leishmania, as demonstrated by a
decrease in 	m and ATP loss (41). As a result, we determined
whether ABCI4 overexpression confers a protective effect against
antimony-inducedmitochondrial dysfunction in Leishmania par-
asites. A decrease in 	m was observed within the first 360 min
post-Sb(III) exposure in both control and ABCI4K/M lines (Fig.
4A); however, 	m was altered to a lesser extent after Sb(III)
exposure in parasites overexpressing ABCI4 (Fig. 4A).
Since 	m is essential for mitochondrial ATP synthesis, its
variation with Sb(III) exposure was monitored in Leishmania
lines. Thus, although a progressive decrease in ATP levels was
observed after Sb(III) treatment (Fig. 4B), parasites overexpress-
ing ABCI4 maintained significantly higher ATP values than con-
trol and ABCI4K/M parasites (Fig. 4B). The above data therefore
provide clear evidence for the ability of ABCI4 to protect against
the mitochondrial toxicity of antimony as manifested by the
maintenance of 	m and ATP levels, probably through reduc-
tion of antimony accumulation.
ROS production induced by Sb(III) exposure in Leishmania
lines. The decrease of 	m induced in Leishmania by a variety of
drug treatments, including antimonials (42), has been associated
with ROS production, which induces damage to the components
of the electron transport chain, disrupts mitochondrial function,
decreases cellular ATP levels, and produces cell death. We there-
fore explored the ability of ABCI4 to protect parasites from ROS
production after treatment with Sb(III). ROS levels were mea-
sured using the cell-permeable probes H2DCFDA and MitoSOX
Red, the latter of which selectively targets mitochondria. After
treatment with Sb(III) for 48 h, it was observed that ROS genera-
tion increased significantly with Sb(III) concentration, in a time-
dependent manner, at both cytosolic and mitochondrial levels
(Fig. 4C and D). The results showed that Leishmania line overex-
pressing ABCI4 generated lower ROS levels than control andmu-
tant lines (Fig. 4C and D), probably due to a decreased intracellu-
lar accumulation of Sb(III). Remarkably, ROS generation
occurred 48 h after treatment with Sb(III), whereas a marked de-
crease in 	m was observed at 60 min (Fig. 4A), thus showing
that the Sb(III)-induced ROS increase is a postmitochondrial
event that is significantly reduced by ABCI4 overexpression.
Infectivity and surveillance of Leishmania lines in mouse
peritoneal macrophages. We analyzed whether ABCI4 overex-
pression confers an advantage in terms of the survival ability of
intracellular amastigotes of Leishmania. Specifically, we deter-
mined the capacity of Leishmania lines to maintain their infectiv-
ity and intracellular replication in mouse peritoneal macrophages
after 72 h postinfection, as a measure of the ability to resist stress
conditions encountered inside the host mammalian cells. Thus,
mouse peritoneal macrophages were infected and the infection
index evaluated at 24 and 72 h postinfection to assess their infec-
tivity and the mean number of amastigotes per infected macro-
phage. In the early stages of infection (24 h postinfection), the
different Leishmania lines showed a similar percentage of infec-
tion inmacrophages (Fig. 5A); similarly, no statistically significant
differences were observed in the percentage of infection after 72 h
of infection (Fig. 5A). In addition, the study of the ability of intra-
cellular amastigotes to replicate inside the host peritoneal macro-
phages showed an increased replication of Leishmania lines over-
expressing ABCI4 versus control and ABCI4K/M parasites after 72
h of infection (Fig. 5B). Consequently, these results lead to the
conclusion that Leishmania lines overexpressing ABCI4 are better
able to survival inside host mammalian cells than the other Leish-
mania lines, although the impact of ABCI4 overexpression on the
biological fitness of these parasites still needs to be explored.
FIG 3 Nonprotein thiol efflux in Leishmania lines. L. major lines pXG (con-
trol; }), ABCI4 (), and ABCI4K/M (Œ) were incubated with (A) or without
(B) 100MSb(III) for 1 h. The promastigotes were thenwashedwith PBS, and
the supernatants processed at different time points, as described in Materials
and Methods. Sample fluorescence (excitation, 380 nm; emission, 510 nm)
was collected using an Infinite F200 luminescence system (Tecan Austria
GmbH) and expressed as relative fluorescence units (RFU). The data are the
means the standard deviation (SD) of three independent experiments. Sig-
nificant differences versus the control line (*, P 
 0.01) were determined by
using the Student t test.
TABLE 3 Metal sensitivity profile of L. major lines in the presence of
BSOa
Compound
Mean EC50 (M) SD [EC50 decrease]
b
pXG ABCI4 ABCI4K/M
Sb(III) 20.87 1.80 53.74 3.35 21.16 3.60
Sb(III) BSOc 9.28 0.48 [2.2]* 15.30 1.23 [3.6]* 11.48 0.96 [1.9]*
Cd(II) 42.36 4.12 82.55 8.84 40.96 2.30
Cd(II) BSO 6.30 0.23 [6.7]* 6.85 0.45 [13.7]* 6.36 0.37 [6.4]*
a Parasites were grown as described in Materials and Methods for 72 h at 28°C in the
presence of increasing concentrations of drugs. Cell viability was determined by using
an MTT-based assay. Data are means from three independent experiments. Significant
differences were determined by the Student t test (*, P
 0.01).
b The EC50 decrease, indicated between brackets, was calculated by dividing the EC50s
after metal treatment by that for metal plus BSO in each Leishmania line.
c 3 mM BSO (a -glutamylcysteine synthetase inhibitor) was added to the culture
medium 48 h before the sensitivity experiment.
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DISCUSSION
ABC transporters are one of the most intriguing protein families
and are of considerable medical significance. However, although
eight subfamilies (ABCA to ABCH) (25) have been identified
since the first ABC transporter, which is involved in drug resis-
tance, was described in Leishmania (43), only a limited amount of
information regarding the functionality of these proteins has been
obtained, mainly as regards drug resistance and lipid/heme traf-
ficking (17, 38). In addition, the family of ABC transporters in
Leishmania contains an unclassified group of proteins termed as
“others” that includes four different transporters with no homol-
ogy with other eukaryotic ABC proteins, but with orthologues in
Trypanosoma brucei and Trypanosoma cruzi (15). We are inter-
ested in the functional characterization of this divergent and un-
classified group of transporters specific to trypanosomatids and
absent in eukaryotic cells. The group “others” includes four dif-
ferent genes, which we have namedABCI1 (LmjF12.1190),ABCI2
(LmjF32.2060), ABCI3 (LmjF33.3040), and ABCI4 (LmjF33.3260),
all of which code for half-transporters with a variable topological
dispositionof theNBDandTMDbutwithacommonrequirement to
formhomo-/heterodimers inorder tobe functionally activeproteins.
We describe here the characterization of ABCI4, a new Leish-
maniaABChalf-transporterwith anunusual structure bearing the
highly conserved NBD at the COOH terminus and TMD at the
NH2 terminus. Coimmunoprecipitation experiments suggest that
ABCI4 homodimerizes, although we cannot discard the possibil-
ity that it forms heterodimers.
We have determined that ABCI4 has a dual localization in both
mitochondria and the PM of Leishmania. Somewhat surprisingly,
a similar dual localization has previously been described for hu-
man ABCB6, which localizes in both the mitochondria and the
PM, thereby contributing to a decreased cellular accumulation of
pheophorbide A and hemin (44). Similarly, human ABCG2 has
been reported to be distributed in both the PMand in intracellular
organelles, including mitochondria, where it regulates ALA-me-
diated protoporphyrin IX levels via export from mitochondria to
the cytosol (45).
We decided to investigate the functionality of ABCI4 by study-
ing the overexpression of this transporter in Leishmania parasites.
Interestingly, we found evidence for the antimony transport ac-
tivity of ABCI4 in Leishmania. Thus, parasites overexpressing
ABCI4 were found to be resistant to antimony as well as to other
metal ions such as As(III), Cd(II), and Pb(II), suggesting that
heavy metals are potential substrates for this transporter.
In addition, ABCI4 overexpression confers resistance to ZPP, a
validated fluorescent heme analog transported by ABCG2 (46).
Similarly, the resistance to antimonials [Sb(III)] was found to be
due to a lower accumulation as a consequence of an increased
FIG 4 Changes of 	m, ATP, and ROS generation in Leishmania lines exposed to Sb(III). L. major lines pXG (control; black histograms), ABCI4 (gray
histograms), and ABCI4K/M (white histograms) were preincubated with 100 M Sb(III) for different times (30, 60, 120, 240, and 360 min) and then incubated
with 5 M JC1 for 10 min for 	m determination (A) or mixed with the same volume of CellTiter-Glo (Promega) for ATP measurement (B), as described in
Materials andMethods. The FL2/FL1 fluorescence ratiowasmeasured by flow cytometric analysis. Parasites were pretreatedwith 10MFCCP for depolarization
control. Intracellular ROS levels were measured using the fluorescent probes H2DCFDA (C) and MitoSOX Red (D). L. major lines pXG (controls; }) and
overexpressing ABCI4 () and ABCI4K/M (Œ) were incubated with different concentrations of Sb(III), as described inMaterials andMethods. (C) After Sb(III)
treatment, parasites were incubatedwith 40 nMH2DCFDA for 30min at 28°C. (D) Prior to the addition of Sb(III), parasites were incubatedwith 5MMitoSOX
for 2 h at 28°C. The fluorescence intensity was determined by flow cytometric analysis and expressed as relative fluorescence units (RFU). The data are themeans
 the SD of at least three independent experiments. Significant differences versus the control line were determined by using the Student t test (*, P
 0.01).
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ABCI4-mediated Sb(III) efflux activity; similar observations were
obtained for Cd(II). Since ABCI4 has a significant ability to efflux
thiol-conjugated complexes, our results suggest that ABCI4 con-
fers resistance to Sb(III) through an efflux of Sb(III)-thiol com-
plexes. Consequently, the ABCI4 transporter could be considered
to be a thiol-X-pump that is able to recognize thiol-conjugated
metals. Furthermore, our findings indicate that the ABCI4 local-
ized in themitochondria is functionally active andmay contribute
to the traffic of porphyrins as parasites overexpressing ABCI4 are
resistant to ZPP, a heme analog, and present a lower accumulation
of fluorescent ZnMP due to a significant efflux. In this context, it
has previously been described that ABC transporters inmitochon-
dria play important roles in the intracellular traffic of heme and
various protoporphyrin intermediates of heme synthesis (47). By
analogy, the LeishmaniaABCC3 (also known as PGPA orMRPA),
which is located in the intracellular vesicular membrane close to
the flagellar pocket, has been described to be involved in arsenite
and antimonial resistance in Leishmania, although it was initially
detected in DNA amplicons (H-circles) of methotrexate-resistant
promastigotes (18, 48). The overexpression of MRPA has been
described to confer resistance to Sb(III) with an EC50 2-fold
increase (19); these results are analogous to the observed in para-
sites overexpressing ABCI4. In addition, the overexpression of
MRPA in combinationwith other proteins such as-glutamylcys-
teine synthase, increase the resistance index to Sb(III) 15-fold
(18). These results support that antimony resistance is a multifac-
torial process that require the combination of different mecha-
nisms to increase the level of resistance. The high levels of ABCC3-
mediated arsenite and antimony resistance in Leishmania are
associated with the sequestering ofmetal-thiol conjugates into the
intracellular vesicles (18). These conjugates may then move out-
side the cell by exocytosis, which occurs exclusively through the
flagellar pocket, or may be extruded directly outside the cell by a
PM thiol-X-efflux pump. Here, the influence of thiol levels on
ABCI4-mediated antimonial resistance was confirmed from the
decrease in the drug sensitivity profile in Leishmania lines after
treatment with BSO and by the ability of this transporter to efflux
thiol-conjugated complexes in the presence of Sb(III). We there-
fore consider that ABCI4 confers resistance to Sb(III) by effluxing
an Sb(III)-thiol complex, thereby suggesting that this transporter
could be considered to be a putative thiol-X-pump.
Several ABC transporters other than ABCC3 also appear to
confermetal resistance by sequestration (49). Thus, the yeast ABC
transporter HMT1 confers cadmium tolerance by sequestering
phytochelatin (a glutathione-like molecule) cadmium complexes
in the fission yeast vacuole (50). Similarly, the yeast ABC trans-
porter YCF1 confers cadmium and arsenite resistance by the vac-
uolar accumulation ofmetal-glutathione complexes (51), amech-
anism that bears a strong resemblance to the MRP1-encoded
transporter found in mammalian cells.
The efflux of Sb(III)-thiol complex observed in the Leishmania
line overexpressing ABCI4 was supported by the decrease in mi-
tochondrial toxicity of antimony, as determined by the mainte-
nance of 	m and ATP levels, as well as by the lower ROS pro-
duction at both a cytosolic and a mitochondrial level.
Leishmania parasites are able to survive inmacrophages, which
provide a hostile environment due to the production and intra-
cellular release of ROS, among other species. Leishmania survives
and replicates by inhibiting the oxidative burst or increasing an-
tioxidant protection (52). Interestingly, we have observed that the
Leishmania line overexpressing ABCI4 has a better survival inside
mouse peritoneal macrophages than the other parasite lines, as
determined by the significantly higher replication at 72 h postin-
fection. Although the mechanism underlying this increased sur-
vival capacity is unknown, we suggest that ABCI4 may be able to
transport unidentified substrates associated with detoxification
mechanisms.
As described previously, Sb(III) resistance is a multifactorial
process (22), with differences in the expression level of the known
proteins involved in the resistance depending on the resistant line
studied, supporting the heterogeneity among drug-resistant par-
asites (6). Omics techniques, including high-throughput sequenc-
ing technologies andmass spectrometry, have been used to screen
the whole genome, transcriptome, and metabolome for detection
of molecular adaptations to antimony resistance in Leishmania;
however, not all changes in expression levels of proteins involved
in Sb(III) resistance are detected in all Leishmania clones resistant
to Sb(III), explaining the fail of these techniques to detect that
ABCI4 is involved in antimony resistance.
In conclusion, overexpression of ABCI4 in the PMmay help to
protect cells against the toxic effects of antimony and other com-
pounds by efflux as conjugated thiol complexes. In addition,
ABCI4 overexpression in mitochondria decreases the toxicity and
accumulation of antimony and porphyrins, probably through ef-
flux of these compounds to the cytosol. Future work should lead
to the obtention of null mutants for ABCI4 that could potentiality
FIG 5 Infectivity and surveillance of Leishmania lines in mouse peritoneal
macrophages. Infection of mouse peritoneal macrophages with stationary
wild-type (WT), pXG (control), ABCI4, ABCI4K/M, and reverted (ABCI4rev)
Leishmania lines using a macrophage/parasite ratio of 1:5 was performed as
described in Materials and Methods. The percentage of infected macrophages
(A) and themeannumber of parasites permacrophage (B)were determined 24
h (black histograms) and 72 h (gray histograms) postinfection. The data are
the means the SD of three independent experiments. Significant differences
versus the control line were determined by using the Student t test (*, P
 0.01
versus respective control).
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be used to understand the role of ABCI4 in Leishmania, and to
determine whether clinical antimony-resistant Leishmania lines
overexpress this transporter.
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